Sunday, October 4, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· December 8, 2025

Macaron AI's Mind Lab Sets New Benchmark with Trillion Parameter RL at 10% Cost, Now Integrated Into NVIDIA Megatron

View original at globenewswire.com
Macaron AI's Mind Lab Sets New Benchmark with Trillion Parameter RL at 10% Cost, Now Integrated Into NVIDIA Megatron Singapore, Dec. 08, 2025 (GLOBE NEWSWIRE) -- For years, progress in AI was driven by one principle: bigger is better…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Despite targeted adaptation, downstream evaluations on unseen benchmarks confirm that the model retains its broad general-purpose capabilities while gaining sharper task alignment

    80% confidence
  • We don't blindly scale up, we scale smarter

    80% confidence
  • Real intelligence learns from real experience

    80% confidence
  • The next leap in AI won't come from a bigger data center, but from a fundamental breakthrough in how machines learn from experience

    80% confidence
  • Slashed the time per RL training iteration by over 6x through a synchronized rollout and training architecture

    80% confidence
  • Training on real user feedback can yield larger performance boosts than simply adding more pre-training data

    80% confidence
  • LoRA-based reinforcement learning on Kimi K2 achieves the same alignment quality with just 10% of the GPU footprint required for full-parameter training

    80% confidence
  • Training runs exhibit smooth, reliable learning curves with steadily increasing rewards and task success rates, free from instability or catastrophic collapse

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com